Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Are you just guessing?
Or did someone in the know actually inform you of this?
Sept-06 press release has lots of golden nuggets in it...
My favorite paragraph being this one: The proceeds of any sale of common stock to White Lion will be used for general corporate purposes including the establishment of a manufacturing operation for the company’s HemoStyp hemostatic gauze product and the completion of all remaining elements of the FDA Premarket Approval application, and to advance the development of powder and gel formats of the company’s patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent.
September 6, 2022 10:11 AM
UNITED HEALTH PRODUCTS ANNOUNCES EQUITY FINANCING AGREEMENT AND PROVIDES CORPORATE UPDATE
Mesquite, NV, Sept. 06, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- United Health Products, Inc. (OTCPK: UEEC), (UHP) today announced that it has entered into a common stock purchase agreement to sell up to $10 million of shares to White Lion Capital, LLC (White Lion), a California-based institutional investor. Under the terms of the purchase agreement, UHP will have the right, in its sole discretion, to sell shares to White Lion over a 36-month term. Any common stock sold to White Lion will occur at a purchase price derived from the prevailing market prices of the company’s common stock at the time of each sale. The company will control the timing and amount of any shares of common stock sold to White Lion, and White Lion is obligated to make purchases at quantities and prices in accordance with the purchase agreement when requested. UHP's ability to make common stock purchase requests is subject to customary limitations and conditions in the stock purchase agreement, including the registration of the resale of the shares on behalf of White Lion under a registration statement to be filed with the SEC on Form S-3.
Separately, the previously announced payments of approximately $1 million to be received by UHP from a former executive of the company have been modified such that the company has received approximately $200,000 and 2,000,000 shares of its common stock are being returned to the company. These shares will be available for reissuance under the above agreement with White Lion.
The proceeds of any sale of common stock to White Lion will be used for general corporate purposes including the establishment of a manufacturing operation for the company’s HemoStyp hemostatic gauze product and the completion of all remaining elements of the FDA Premarket Approval application, and to advance the development of powder and gel formats of the company’s patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent.
Regarding the company’s previously disclosed legal action relating to the audit of its 2017 financial statements, on August 31, 2022 the company and the defendant entered into a settlement agreement under which, among other provisions, UHP will receive a cash payment this month.
Brian Thom, UHP’s Chief Executive Officer, commented: “The resolution of this outstanding litigation, combined with the White Lion transaction and the settlement of payments from our former executive, will provide the company with over $1 million in capital to advance its business plan without diluting shareholders.”
Regarding the company’s FDA PMA application process, UHP continues to work with its intended manufacturing partner and its regulatory consultant, Regulatory Compliance Associates, to establish production and complete all necessary documentation. UHP is auditing the production facility as well as its documentation and employee training processes, among other elements of the partner’s operations. The company’s manufacturing equipment will commence production, allowing for the completion of Standard Operating Procedure and Design Control documentation, and the development of the Design Transfer process that will transfer detailed product design information to the manufacturing partner. It is anticipated that the completion of the audit process, establishment and inspection of gauze production, drafting of associated documentation, and testing of product to ensure conformance with previous product specifications will be completed within 60 days. In the interim, the company will continue to provide updates on achievement of milestones in this process.
There can be no assurance that the company’s PMA application will be approved.
Investor relations:
info@unitedhealthproductsinc.com
475.755.1005
Philippe Niemetz
212 344-6464
p.niemetz@panconsultants.com
About United Health Products -- United Health Products develops, manufactures and markets HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and consumer markets, and is focused on gaining approval to access the human surgical market.
For more information on UHP visit: www.unitedhealthproductsinc.com or contact the company at info@unitedhealthproductsinc.com
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.
News Provided by GlobeNewswire via QuoteMedia
https://bit.ly/3R8336X
CEO was given shares @$0.30 in payment of salary in lieu of cash payment.
$UEEC filed SEC form 4: Chief Executive Officer Thom Brian David: Granted 150,000 of Common shares at price $0.3 on 2022-09-16, increased holding by 16% to 1,112,141 shares.
Explanation of Responses:
Remarks:
The Common Shares were issued by the Issuer to the Reporting Person pursuant to Rule 16b-3(d)(1) in payment of salary in lieu of cash payment.
8:44 AM · Sep 20, 2022
https://www.otcmarkets.com/filing/html?id=16087802&guid=JF--kWqp5N5HJth
What are the factors that would send this stock into dollarsville?
Hopefully you know what to do today.
BAGHOLDERS HAVE AN OPPORTUNITY TODAY.
Last week OTCX MM was constantly on the offer, downticking, and selling every bid in sight. Sometimes OTCX can be a dilutor and/or a short seller too.
Does_anyone_want_to_admit_to_dumping their large stock position?
Or know who is responsible for it?
We're here for the 100%_to_1000% profit overnight.
Reminder: SEC-form-8K states July-13-2022 is PMA FDA meeting date.
"Regarding the previously announced meeting with the FDA to review the Company’s Class III Premarket Approval application, this meeting has been moved to July 13 from July 6 at the FDA’s request. As of this date, the Company has received no additional requests for information or questions from the FDA on its PMA application."
https://bit.ly/3uqtxb0
What time is the meeting today?
Come Mister tally man, tally me banana
Offers are heavy and down ticking this morning.
SEC_8K_filed, $ALRT has terminated the right to distribute 101,025,092 unrestricted shares of common stock at a price of $0.05 per share pursuant to the Prospectus.
https://www.otcmarkets.com/filing/html?id=15939136&guid=Y1U-kHKnD2xpJth
SIMPQ CDEL 1.2M bid size at .6426. Looks like someone sold short a few days ago at 0.01 + 0.02 per share and for some odd reason they are covering at the market offers.
SIMPQ CDEL 1.2M bid size at .6426. Looks like someone sold short a few days ago at 0.01 + 0.02 per share and for some odd reason they are covering at the market offers.
Hi SportyNorty, I'd like to hear more about how you've come to this conclusion. Do you have time to share the details? Thank you.
UEEC FDA PMA meeting in 6-business-days.Regarding the previously announced meeting with the FDA to review the Company’s Class III Premarket Approval application, this meeting has been moved to July 13 from July 6 at the FDA’s request. As of this date, the Company has received no additional requests for information or questions from the FDA on its PMA application. https://www.otcmarkets.com/filing/html?id=15884168&guid=LFnwknM0-dYKJth
Interesting 8K, preparing for the FDA PMA approval?
https://sec.report/Document/0001477932-22-004603/
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 16, 2022, the Board of Directors of United Health Products, Inc. (the “Company”) approved the following compensatory arrangements for certain of its officers and directors:
In recognition of his agreement to accept stock in lieu of cash salary since his appointment in December 2020, his financial support for the Company through approximately $500,000 of cash loans during the period when the ongoing Securities and Exchange Commission (“SEC”) investigation of the Company restricted its ability to access external capital, and his efforts to successfully negotiate a settlement with the SEC, the Company has amended the Restricted Stock Unit Agreement of Brian Thom, the Company’s Chief Executive Officer and Chairman Pro Tempore (the “Thom RSU Agreement”), to increase the RSU grant by 15% to 13.225 million from 11.50 million RSUs, and to increase the portion of such grant that would vest upon the receipt of a Premarket approval from the Food and Drug Administration to 20% from 5%. All other terms of the Thom RSU Agreement remain unchanged.
In recognition of his expanded duties as Independent Director and his contribution to the resolution and settlement of the SEC investigation, the Company has entered into a Restricted Stock Unit Agreement with Robert Denser wherein he has received a grant of 1.0 million RSUs which shall vest upon the earlier of the Company generating $30,000,000 of cumulative revenue starting in January 2022 or the occurrence a Trigger Event which generally represents a change of control transaction by the Company. Mr. Denser has received no other compensation for his service to the Company since 2019.
Item 8.01. Other Events.
On June 15, 2022, the SEC's investigation of the Company, initially reported in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, was settled through the filing of a consent judgment on the terms which were previously described in the Company’s Form 8-K filed on April 29, 2022, without the Company admitting or denying the SEC's allegations.
In a separate settlement agreement between the SEC and Mr. Douglas Beplate, the Company’s former Chief Executive Officer and a Director, Mr. Beplate will, among other things, make disgorgement payments to the Company totaling $1,020,000 over the next six months.
The Company issued a press release on June 16, 2022, providing an update on its settlement with the SEC. A copy of the press release is being furnished herewith as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit
Number
Description
10.1
Brian Thom Restricted Stock Unit Agreement dated November 24, 2020 (Incorporated by reference to the Form 8-K dated December 2, 2020)
10.2
Amendment to Brian Thom November 24, 2020 RSU Agreement
10.3
Robert Denser Restricted Stock Unit Agreement dated June 17, 2022
99.1
Press release, dated June 16, 2022
104
Cover Page Interactive Data File (formatted as Inline XBRL)
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized, on June 22, 2022.
United Health Products, Inc.
By:
/s/ Brian Thom
Brian Thom
Principal Executive Officer
By:
/s/ Kristofer Heaton
Kristofer Heaton
Principal Financial Officer
R..U.. anticipating updates today or this long weekend?
SEC Form 8K this morning:
https://www.otcmarkets.com/filing/html?id=15884168&guid=BmpwkFe7wojKJth
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 8, 2022
UNITED HEALTH PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Nevada
000-27781
84-1517723
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)
10624 S. Eastern Ave., Ste. A209
Henderson, NV 89052
(Address of principal executive offices, zip code)
(877) 358-3444
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (See General Instruction A.2. below):
? Written communication pursuant to Rule 425 under the Securities Act (17 CFR 23.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 24.14a-12)
? Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 24. 13e-4(c))
Securities registered pursuant to Section 12 (b) of the Act: None
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ?
Item 7.01 Regulation FD Disclosure.
In connection with the Securities and Exchange Commission’s investigation against United Health Products, Inc., Douglas Beplate (the former Chief Executive Officer and Chairman and a former director of the Company), and Louis Schiliro, (the former Chief Operating Officer and a former director of the Company, and a current contractor with the Company), concerning possible violations of certain provisions of the Securities Act of 1933 and the Securities Exchange Act of 1934, the Company advised the Commission’s Enforcement Division that it would accept the proposed settlement terms which the Enforcement Division had previously presented to the Company. The Company was informed that the Commission approved the Enforcement Division’s recommended settlement terms to resolve the matter. The settlement process includes the Commission filing a complaint followed in due course by the filing of a consent judgment reflecting the terms of settlement. In that regard, the Commission filed a complaint in the U.S. District Court for the District of New Jersey on June 8, 2022, and Company’s understanding is that once a judge is assigned, the consent judgement will be filed to settle the matter. The Commission’s investigation and the proposed settlement terms were previously reported by the Company in its prior periodic reports including its Annual Report for the year ended December 31, 2021 under Item 1A “Risk Factors”, and its Current Report on Form 8-K filed on April 29, 2022 which disclosure is incorporated into this report by reference. The proposed settlement terms pertaining to the Company do not include settlement terms in the investigation pertaining to Mr. Beplate and Mr. Schiliro.
Regarding the previously announced meeting with the FDA to review the Company’s Class III Premarket Approval application, this meeting has been moved to July 13 from July 6 at the FDA’s request. As of this date, the Company has received no additional requests for information or questions from the FDA on its PMA application.
The information in this Current Report is being furnished pursuant to Item 7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor is it subject to the liabilities of that section or deemed incorporated by reference in any filing by the Company under the Exchange Act, unless specifically identified as being incorporated therein. By furnishing this Current Report on Form 8-K, the Company makes no admission as to the materiality of any information in this Report.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
United Health Products, Inc.
Dated: June 10, 2022
/s/ Brian Thom
Brian Thom, Chief Executive Officer
3
Lack of shares is not an issue here.
Yes the sellers are having lots of fun!
Form 10-Q filed by ALR TECHNOLOGIES INC. $ALRT
$ALRT
https://ih.advfn.com/stock-market/USOTC/alr-technologies-qb-ALRT/stock-news/88121866/quarterly-report-10-q
$ALRT
How did you find this information, where does OTCmarkets post these types of details? Do you happen to have a link? Thank you.
Did you receive today's PR before it was published to the street?
Thank you.
SEC-Form-8K filed showing convertible shares being sold.
https://www.otcmarkets.com/filing/html?id=15737728&guid=TcewkaseQ9xjdth
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 18, 2022
HIMALAYA TECHNOLOGIES, INC.
(Exact name of Registrant as specified in its Charter)
NEVADA 000-55282 26-0841675
(State or other jurisdiction
of incorporation)
(Commission
File No.)
(IRS Employer
Identification No.)
1 E Erie St, Ste 525 Unit #2420, Chicago, IL 60611
(Address of principal executive offices)
(630) 708-0750
(Registrant’s Telephone Number)
(Former name or address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
? Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
? Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
? Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
? Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading symbol(s) Name of each exchange on which registered
Common HMLA OTC PINK
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2) ?
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ?
Himalaya Technologies, Inc. p/k/a Homeland Resources Ltd. is referred to herein as “Himalaya”, “we”, “us”, or “the Company”.
Item 8.01 Other Events.
On April 14, 2022, a third-party converted $18,100.00 of a 12% junior note into 5,838,710 common shares reducing its loan balance to $20,475.07 including interest and penalties. The loan was funded in 2014 and is in default.
The Company owes a third-party lender $151,500.00 in principal plus 10% interest accrued since the loan was funded on June 29, 2021. The loan is not in default.
On April 18, 2022, our CEO Vikram Grover elected to convert $80,000.00 of compensation accrued 08/01/21 – 03/31/2022 into 15,504 Series B Preferred shares of our stock based on a moving average price in common shares of .00516. The conversion reduced Mr. Grover’s accrued compensation balance to zero.
As of April 19, 2022, we had total outstanding common shares of 139,618,502, total restricted shares of 18,705,430 and a free trading float of 120,913,072 common shares.
Item 9.01. Exhibits
(a) Exhibits. The following exhibits are filed with this Current Report on Form 8-K:
Exhibit No. Description
10.1 Himalaya Technologies, Inc. Vikram Grover Employment Letter August 1, 2021
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HIMALAYA TECHNOLOGIES, INC. p/k/a
HOMELAND RESOURCES LTD.
Date: April 19, 2022 By: /s/ Vikram Grover
Vikram Grover
Chief Executive Officer
Exhibit 10.1
Even if we see_the recipe, the_cake_is_already_baked.
Everyone here already knows the news as per the company's spokesman on this iHub board.
$LSYN SEC has revoked their securities. https://bit.ly/3JMKuBi
Yes they will be converting those warrants to cash, and yes it is the CEO.
SEC Form 3 filed by Grover Vikram P.
50,000,000 warrants of common shares convertible at a price of $0.0001
https://www.sec.gov/Archives/edgar/data/0001409624/000149315222009801/xslF345X02/ownership.xml
SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Grover Vikram P
(Last) (First) (Middle)
2810 BRISTOL DR #309
(Street)
LISLE IL 60532
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
04/13/2022 3. Issuer Name and Ticker or Trading Symbol
HIMALAYA TECHNOLOGIES, INC [ HMLA ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
X Officer (give title below) Other (specify below)
CEO, Chairman
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
SERIES B PREFERRED 150,000 D
SERIES B PREFERRED 150,000(1) I 150,000 through entity controlled by filer
SERIES C PREFERRED 1,000,000 D
Book Recommendation: Profit from Legal Insider Trading: Invest Today on Tomorrow's News
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
WARRANTS 06/22/2021 06/22/2026 Common 50,000,000 0.0001 I Through entity controlled by filer
Explanation of Responses:
1. Filer owns shares indirectly through FOMO CORP., a company he controls as Chairman/CEO.
Remarks:
Series B Preferred shares convert 1-1000 into common shares and vote on an as converted basis. Series C Preferred shares convert 1-1 into common shares and vote on a 1-100,000 basis.
/s/ Vikram P Grover 04/13/2022
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Always a great sell if you got em.
Hmmm... which broker do you use?
Most OTC/PINK stories end with a classic reverse-split which essentially devalues all of the existing investors in a stock.
GAXY / GAXYD most recent example with a 1:200 reverse split. https://www.otcmarkets.com/stock/GAXYD/security
reverse merger incoming soon?
What is your reasoning behind your statement?